[35]TillmannHL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment[J]. World J Gastroenterol, 2014, 22:6701-6706.DOI:10.3748/wjg.v20.i22.6701. [36]Kidney Disease: Improving Global Outcomes KDIG...
Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype3 ...
IJN12, IJN13, IJN16, and IJN19, tend to have higher molecular weight, implying low water solubility and narrowing the window of concentrations allowable for treatment options. However, the predicted effective doses of the representative compounds against HCV are very low, potentially compensating fo...
Although such drug-policy reform remains controversial, its results merit conducting a pilot study that would combine the decriminalisation policy with intervention to scale up BBVSTIs testing, treatment and prevention programs for SD users as an alternative to harsh penalties in China. This might ...
What is the appropriate treatment approach after a diagnosis of reinfection? Recommendation All patients with documented reinfection, regardless of the route of transmission, should be offered retreatment with DAAs as soon as is practically possible as per individual country guidelines. Arbitrary limits on...
Hepatitis B and C viruses (HBV and HCV) are significant causes of chronic liver diseases, with approximately 350 million infections globally. To accelerate the finding of effective treatment options, we introduce HBCVTr, a novel ligand-based drug design
A consensus, of course, has not been reached regarding core antigen testing. The most recent guidelines from the American Association for the Study of Liver Diseases (AASLD) still recommend quantitative HCV viral load testing after 4 weeks of treatment, meaning that patients are expected to undergo...
Advances in HCV antigen detection technologies can apparently reduce the window period for anti-HCV antibodies, providing new clinical evidence for the early detection, diagnosis, and treatment of HCV infection. This article is a current review of HCV antigen detection methodologies, clinical ...
The development and availability of highly effective direct-acting antiviral agents (DAAs) have revolutionised HCV management and provide the therapeutic tools required to strive for elimination. For HCV treatment as prevention to have greatest impact, HCV testing and treatment coverage must be high, wi...
The national guidelines for simplified HCV treatment were used to determine treatment eligibility [10]. Individuals who were unwilling or unable to provide informed consent, had an impaired renal function, were pregnant, were taking prohibited concomitant medication, or had a significant illness that ...